

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF FOSUN PHARMA FOR THE YEAR ENDED 31 DECEMBER 2009

Reference is made to the overseas regulatory announcement dated 24 March 2010 (the "**Announcement**") and issued by Fosun International Limited (the "**Company**") in relation to the extract of the annual report for the year ended 31 December 2009 of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of the Company and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196).

The board of directors of the Company would like to draw the attention of its shareholders and the investment public to the following principal financial data and indicators of Fosun Pharma for the year ended 31 December 2009 as set out in the Announcement:

Principal Financial Data

Unit: Yuan Currency: RMB

	2009	2008	Increase/decrease of this period as compared with the same period last year (%)	2007
Operation revenue	3,872,256,326.96	3,773,234,220.82	2.62	3,693,301,678.63
Profit before tax	3,264,668,429.22	835,675,877.22	290.66	756,374,586.63
Net profit attributable to shareholders of the listed company	2,498,201,836.08	690,856,541.85	261.61	625,781,242.25

Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	374,112,529.25	325,910,005.34	14.79	325,854,485.71
Net cash flow from operating activities	261,867,525.18	233,041,247.51	12.37	131,477,131.38
	End of 2009	End of 2008	Increase/decrease as at the end of this period as compared with the end of the same period last year (%)	End of 2007
Total assets	11,527,145,937.29	7,538,918,031.88	52.90	7,434,985,230.95
Owners' equity (or shareholders' equity)	6,476,522,231.34	4,008,859,534.34	61.56	3,872,266,150.87

Principal Financial Indicators

	2009	2008	Increase/decrease of this period as compared with the same period last year (%)	2007
Basic earnings per share (RMB/share)	2.02	0.56	260.71	0.51
Diluted earnings per share (RMB/share)	2.02	0.56	260.71	0.51
Basic earnings per share net of non-recurring gain or loss (RMB/share)	0.30	0.26	15.38	0.26
Weighted average return on net assets (%)	47.93	17.55	Increased by 30.38 percentage point	17.76
Weighted average return on net assets net of non-recurring gain or loss (%)	7.18	8.28	Decreased by 1.10 percentage point	9.25
Net cash flow per share from operating activities (RMB/share)	0.21	0.19	10.53	0.11

	End of 2009	End of 2008	Increase/decrease as at the end of this period as compared with the end of the same period last year (%)	End of 2007
Net assets attributable to shareholders of the listed company per share (RMB/share)	5.23	3.24	61.42	3.13

The operation revenue of Fosun Pharma in 2010 is expected to increase more than 20% as compared with 2009.

Note: The full text of the annual report for the year ended 31 December 2009 of Fosun Pharma will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

24 March 2010, Shanghai, the PRC

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetang and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.